Data / Form D filings / Axonis Therapeutics, Inc.
Axonis Therapeutics, Inc.: Form D filing
Axonis Therapeutics, Inc., a biotechnology company in Boston, MA, filed a Form D with the SEC in 2024. The latest, on November 1, 2024, reports $46 million sold of a $115 million offering to 19 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 75 KNEELAND STREET, 14 FL, Boston, MA, 02111
- Phone
- (617) 299-8479
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2043170
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 1, 2024 | New notice | $115,000,000 | $46,000,000 | $69,000,000 | 19 | Oct 18, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Donald J. Manning, M.D., Ph.D | Executive Officer | |
| Jeffrey Imbaro | Executive Officer | |
| Corey . Goodman | Director | |
| Brock Reeve | Director | |
| Shane . Hegarty | Executive Officer | |
| Joanna Stanicka | Executive Officer, Director | |
| Jonathan J. Leff | Director | |
| Raymond J. Kelleher | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Oct 28, 2024 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Axonis Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.